Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Top Cited Papers
Open Access
- 9 March 2006
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 354 (10), 1021-1030
- https://doi.org/10.1056/nejmoa053583
Abstract
High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival.Keywords
This publication has 31 references indexed in Scilit:
- Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myelomaCancer, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesBlood, 2005
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With MyelomaJournal of Clinical Oncology, 2003
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958